Search

The article discusses medications that can be used as treatment for pediatric attention-deficit/hyperactivity disorder (ADHD) to address the shortage of prescription stimulants in the U.S. Topics discussed include the results of a clinical study of the dextroamphetamine patch Xelstrym, the contraindications and adverse drug effects of lisdexamfetamine dimesylate (Vyvanse), and the administration of viloxazine (Qelbree). Also discussed are other medications including atomoxetine and clonidine.

Large doses of prescription amphetamine have been associated with a more than five‐fold increased risk of new‐onset psychosis or mania, according to Belmont, Massachusetts‐based McLean Hospital researchers of a new study published online Sept. 12 in the American Journal of Psychiatry. [ABSTRACT FROM AUTHOR]

The article reflects the views of the risks of stimulant pharmacotherapy is the well-documented effect of medication on appetite and growth, which include COVID-19 pandemic has complicated the practice of child and adolescent psychiatry and psychology with benefits of stimulant pharmacotherapy.

The article focuses on executive function refers to a multifaceted construct that encompasses a variety of cognitive processes has required to maintain an appropriate problem-solving for attainment of future goals and components of EF vary widely across studies depending on operational definitions.

A recent study conducted by researchers at Brigham and Women's Hospital and Harvard University Medical School examined the potential impact of prescription stimulant use during pregnancy on the risk of neurodevelopmental disorders in children. The study analyzed health care utilization data from publicly insured and commercially insured pregnant individuals in the US. The findings suggest that exposure to amphetamine/dextroamphetamine and methylphenidate during pregnancy is unlikely to significantly increase the risk of childhood neurodevelopmental disorders. However, methylphenidate exposure was associated with an increased risk of ADHD. Further research is needed to better understand the potential effects of these medications on fetal development. [Extracted from the article]

The article reports that Azurity Pharmaceuticals is recalling Zenzedi CII 30 mg, a drug used for narcolepsy and Attention-deficit/hyperactivity disorder due to a product mix-up where the antihistamine drug carbinoxamine was found in one bottle. Potential risks for patients include drowsiness, CNS depression, increased eye pressure, and other adverse effects.

2021 NOV 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

2021 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Drugs and Therapies - Central Nervous System Agents have [...]

The article highlights the report that examine the assessment and treatment of Attention-deficit hyperactivity disorder in older adults.

The article focuses on the symptoms and parenting behavior associated with attention-deficit/hyperactivity disorder among parents.

2020 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Vallon Pharmaceuticals reported the presentation of positive data from a pilot study assessing human abuse liability for its investigational Abuse Deterrent Amphetamine Immediate Release (ADAIR). The data were presented at [...]

2020 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - COX-2 Inhibitors. According [...]

The article reports on the FDA's approval of generic versions of Vyvanse, a medication used to treat ADHD and binge-eating disorder. These generics, approved for use in children and adults, come from 15 different manufacturers and aim to address shortages of Vyvanse due to manufacturing delays and increased demand.

No. 8,597,684 describes a composition containing a mixture of a pH-independent, modified release barrier coated amphetamine-ion exchange resin complex, an uncoated amphetamine-ion exchange resin complex, and an optional uncomplexed amphetamine or salt thereof. "US 2004/0220277 and WO 2004/071501 describe amphetamine compositions in which the molar ratio of l-amphetamine to d-amphetamine released therefrom in a time period later in the day is higher than the ratio released in a time period earlier in the day. "US Reissue Patents 41,148 and RE 42,096 describe oral pulsed dose amphetamine delivery systems having an immediate release amphetamine and a delayed enteric release amphetamine component with mixed amphetamine salts. [Extracted from the article]

Keywords: Adrenergic Agent; Adrenergic Uptake Inhibitor; Amphetamine; Amphetamines; Business; CNS Stimulants; Central Nervous System Agents; Central Nervous System Stimulants; Dextroamphetamine; Dextroamphetamine Therapy; Dopamine; Drugs and Therapies; Ethylamines; FDA; Glenmark Pharmaceuticals Ltd; Health and Medicine; Marketing and Licensing Agreements; Organic Chemicals; Pharmaceutical Companies; Pharmaceuticals; Phenethylamines; Regulatory Agencies; U.S. Food and Drug Administration EN Adrenergic Agent Adrenergic Uptake Inhibitor Amphetamine Amphetamines Business CNS Stimulants Central Nervous System Agents Central Nervous System Stimulants Dextroamphetamine Dextroamphetamine Therapy Dopamine Drugs and Therapies Ethylamines FDA Glenmark Pharmaceuticals Ltd Health and Medicine Marketing and Licensing Agreements Organic Chemicals Pharmaceutical Companies Pharmaceuticals Phenethylamines Regulatory Agencies U.S. Food and Drug Administration 2023 MAR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Glenmark Pharmaceuticals Inc., USA and Cediprof, Inc. (a part of the Neolpharma Pharmaceutical Group family of companies) have entered into an exclusive supply and distribution agreement for Cediprof's FDA-approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, the generic version of Adderall(R)1 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. Glenmark expects to commence distribution of the product in the U.S. during the second half of 2023. [Extracted from the article]

2019 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Urologic Diseases and Conditions - Urinary Incontinence are presented in a [...]

2019 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Digestive System Diseases and Conditions - Microscopic Colitis are discussed in [...]

2019 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Life Science Research - Biology have been published. [...]

2019 MAY 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Central Nervous System Agents [...]

The article reports on therapeutic exchange initiative from lisdexamfetamine to amphetamine/dextroamphetamine extended-release (ER) led to a significant decrease in the overall costs of long-acting stimulant medications. It mentions that Researchers conducted a single-center, retrospective cohort study with rural pediatric and adolescent behavioral health facility admitted to the acute program and residential treatment center developed a therapeutic interchange.

2018 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Phenethylamines - Amphetamines are presented in a new report. [...]

2018 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Pharmacology - Pharmacokinetics have been published. According to [...]

Attention deficit hyperactivity disorder (ADHD) is a mental health condition that affects how people focus, sit still and control their behavior. ADHD typically begins during childhood and can continue into adulthood. [ABSTRACT FROM AUTHOR]

Introduction: Currently, there are a number of pharmaceuticals available that have potential to enhance cognitive functioning, some of which may ultimately be considered for such use in military operations. Some drugs with potential for cognition enhancement have already been studied for use in military operations specific to their primary effect in sleep regulation (i.e., dextroamphetamine, modafinil, caffeine). There is considerable information available on many of these drugs. However, considerations for military appropriateness must be based on proficient research (e.g., randomly controlled trial design). Methods: A meta-analysis was conducted to summarize the current state of knowledge of these potentially cognition-enhancing drugs. The analysis only included studies which met inclusion criteria relevant to military research. Results: The results of the literature review reveal a gap in research of the enhancement properties of the drugs of interest. The results yielded three studies (all of which studied modafinil) that met the criteria. The metaanalysis of these three studies revealed a relatively weak pooled effect of modafinil on some aspects of cognitive performance in normal, rested adults. Discussion: While the results of this study support the efficacy of modafinil, the main finding is the large literature gap evaluating the short- and long-term effects of these drugs in healthy adults. [ABSTRACT FROM AUTHOR]

Introduction: Successful military aviation operations depend on maintaining continuous day-night operations. Stimulants are easy to use and popular for sustaining performance because their utility is not dependent upon environmental or scheduling modifications. Dextroamphetamine is authorized for use by the aircrews of all U.S. military services, but its potential for abuse and subsequent addiction is of aeromedical concern. Finding an alternative stimulant, such as modafinil, that displays a low affinity for dopamine uptake binding sites would prove extremely beneficial. This study sought to establish the efficacy and safety of modafinil during actual flying operations, thus providing the operational validity desired to approve the use of modafinil for helicopter flight operations. Methods: During two, 40-h periods of sustained wakefulness, 18 helicopter pilots (17 men, 1 woman, mean years of age = 29.5) each completed 15 flights and other evaluations, during which they received 2 of 3 experimental conditions: 3 doses at 4-h intervals of modafinil (100 mg), dextroamphetamine (5 mg), or placebo. Results: Statistical results showed that modafinil, like dextroamphetamine, maintained alertness, feelings of well-being, cognitive function, judgment, risk perception, and situation awareness of sleep-deprived aviators consistently better than placebo and without side effects of aeromedical concern. Discussion: Like previous research, this study strongly suggests that both drugs can maintain acceptable levels of mood and performance during sleep deprivation. The results also confirm that modafinil is well tolerated and appears to be a good alternative to dextroamphetamine for countering the debilitating mood and cognitive effects of sleep loss during sustained operations. [ABSTRACT FROM AUTHOR]

The FDA's Office of Prescription Drug Promotion, after reviewing a link for ProCentra (dextroamphetamine sulfate) on Google, sent a warning letter to Outlook Pharmaceuticals saying that the "link is false or misleading in that it presents information about the benefits of ProCentra, but fails to include any risk information about the drug." There's nothing wrong with the medication, which is approved by the FDA. But there is something wrong with the ad, and the FDA wanted it off the internet immediately. The company called it ProCentra only, never naming the established name, which constitutes misbranding within the federal Food, Drug, and Cosmetic Act and makes distributing it a violation. "These are especially concerning from a public health perspective because they create a misleading impression about the safety of ProCentra, a drug that is a schedule II controlled substance used in the vulnerable pediatric patient population, and bears a Boxed Warning that describes the high potential for abuse, that administration of amphetamines for prolonged periods of time may lead to drug dependence, and states that misuse may cause sudden death and serious cardiovascular adverse events," the letter states. [ABSTRACT FROM AUTHOR]

'Women and men may respond differently to the effects of stimulants such as amphetamine and cocaine. In order to assess potential sex differences in the reinforcing effects of d-amphetamine, a [...]

Isotretinoin tablets (Claravis) 10, 20, and 40 mg (equiv to Accutane tablets) to be marketed beginning this month BARR LABORATORIES Amphetamine and dextroamphetamine tablets 7.5, 12.5, and 15 mg (total) [...]

The article focuses on the issue due to increasing misuse of Adderall drug by young adults as a drug to help them study or to party. Topics discussed are treating of attention deficit hyperactivity disorder (ADHD) and narcolepsy; warning by the U.S. Food and Drug Administration, and need for diversion to curb the non medical use of Adderall.

A recent study with open-label and double-blind placebo-controlled phases examined the potential role of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, in the treatment of negative symptoms in schizophrenia. Because this [...]

The article describes cases of ischaemic stroke in three patients, 2 men and 1 woman, aged 23 to 37 years, following treatment with amfetamine/dexamfetamine (dextroamphetamine) or lisdexamfetamine with one of the patients developing ischaemic stroke on lisdexamfetamine treatment.

The article reports on the result of a study which unveils the cost effectiveness of Lisdexamfetamine dimesylate in treating patients with binge-eating disorder (BED) in the U.S.

The article presents a case study of a 17-year-old girl who developed hypertension, mydriasis, headache, blurred visions, nausea, vomiting and chest pain after overdosing with lisdexamfetamine.

An abstract of the article "Derealization due to dextroamphetamine: A rare side effect which could cause premature discontinuation of treatment," by A. Ghaffarinejad and colleagues is presented.